Literature DB >> 29264424

Surgical management of adolescent and young adults with gastrointestinal stromal tumors: it is of value?

Francis Esposito1, Joan Maurel1.   

Abstract

Entities:  

Year:  2017        PMID： 29264424      PMCID： PMC5723740          DOI： 10.21037/tgh.2017.10.05

Source DB:  PubMed          Journal:  Transl Gastroenterol Hepatol        ISSN： 2415-1289


× No keyword cloud information.
  16 in total

1.  Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study.

Authors:  Martine Van Glabbeke; Jaap Verweij; Paolo G Casali; Axel Le Cesne; Peter Hohenberger; Isabelle Ray-Coquard; Marcus Schlemmer; Allan T van Oosterom; David Goldstein; Raf Sciot; Pancras C W Hogendoorn; Michelle Brown; Rossella Bertulli; Ian R Judson
Journal:  J Clin Oncol       Date:  2005-08-20       Impact factor: 44.544

2.  Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib.

Authors:  Sebastian Bauer; Jörg Thomas Hartmann; Maike de Wit; Hauke Lang; Florian Grabellus; Gerald Antoch; Wolfgang Niebel; Jochen Erhard; Peter Ebeling; Matthias Zeth; Georg Taeger; Siegfried Seeber; Michael Flasshove; Jochen Schütte
Journal:  Int J Cancer       Date:  2005-11-01       Impact factor: 7.396

3.  Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST.

Authors:  Alessandro Gronchi; Marco Fiore; Francesca Miselli; Maria Stefania Lagonigro; Paola Coco; Antonella Messina; Silvana Pilotti; Paolo Giovanni Casali
Journal:  Ann Surg       Date:  2007-03       Impact factor: 12.969

4.  Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.

Authors:  S Hirota; K Isozaki; Y Moriyama; K Hashimoto; T Nishida; S Ishiguro; K Kawano; M Hanada; A Kurata; M Takeda; G Muhammad Tunio; Y Matsuzawa; Y Kanakura; Y Shinomura; Y Kitamura
Journal:  Science       Date:  1998-01-23       Impact factor: 47.728

5.  Surgical resection of gastrointestinal stromal tumors after treatment with imatinib.

Authors:  Robert H I Andtbacka; Chaan S Ng; Courtney L Scaife; Janice N Cormier; Kelly K Hunt; Peter W T Pisters; Raphael E Pollock; Robert S Benjamin; Michael A Burgess; Lei L Chen; Jonathan Trent; Shreyaskumar R Patel; Kevin Raymond; Barry W Feig
Journal:  Ann Surg Oncol       Date:  2007-01       Impact factor: 5.344

6.  Post-imatinib surgery in advanced/metastatic GIST: is it worthwhile in all patients?

Authors:  C Mussi; U Ronellenfitsch; J Jakob; E Tamborini; P Reichardt; P G Casali; M Fiore; P Hohenberger; A Gronchi
Journal:  Ann Oncol       Date:  2009-07-23       Impact factor: 32.976

7.  Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

Authors:  Charles D Blanke; Cathryn Rankin; George D Demetri; Christopher W Ryan; Margaret von Mehren; Robert S Benjamin; A Kevin Raymond; Vivien H C Bramwell; Laurence H Baker; Robert G Maki; Michael Tanaka; J Randolph Hecht; Michael C Heinrich; Christopher D M Fletcher; John J Crowley; Ernest C Borden
Journal:  J Clin Oncol       Date:  2008-02-01       Impact factor: 44.544

8.  Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib -- analysis of prognostic factors (EORTC-STBSG collaborative study).

Authors:  S Bauer; P Rutkowski; P Hohenberger; R Miceli; E Fumagalli; J A Siedlecki; B-P Nguyen; M Kerst; M Fiore; P Nyckowski; M Hoiczyk; A Cats; P G Casali; J Treckmann; F van Coevorden; A Gronchi
Journal:  Eur J Surg Oncol       Date:  2014-01-15       Impact factor: 4.424

9.  Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group.

Authors:  Jean-Yves Blay; Axel Le Cesne; Isabelle Ray-Coquard; Binh Bui; Florence Duffaud; Catherine Delbaldo; Antoine Adenis; Patrice Viens; Maria Rios; Emmanuelle Bompas; Didier Cupissol; Cecile Guillemet; Pierre Kerbrat; Jérome Fayette; Sylvie Chabaud; Patrice Berthaud; David Perol
Journal:  J Clin Oncol       Date:  2007-03-20       Impact factor: 44.544

10.  PDGFRA activating mutations in gastrointestinal stromal tumors.

Authors:  Michael C Heinrich; Christopher L Corless; Anette Duensing; Laura McGreevey; Chang-Jie Chen; Nora Joseph; Samuel Singer; Diana J Griffith; Andrea Haley; Ajia Town; George D Demetri; Christopher D M Fletcher; Jonathan A Fletcher
Journal:  Science       Date:  2003-01-09       Impact factor: 47.728
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.